Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model

Experimental Hematology

Volumn 37, Issue 5, 2009, Pages 593-603

  Hayun, Michal ^a   Saida, Hagar ^a   Albeck, Michael ^a   Peled, Alpha ^b   Haran Ghera, Nechama ^b   Sredni, Benjamin ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; CD81 ANTIGEN; FIBRONECTIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN G2B; MELPHALAN; TETRASPANIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL ADHESION; CELL DIVISION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ETHYLENES; FIBRONECTINS; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELPHALAN; MICE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PARAPROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 64249108542     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.01.006     Document Type: Article

References (35)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
2. Mitsiades C.S., Mitsiades N.S., Munshi N.C., Richardson P.G., and Anderson K.C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 42 (2006) 1564-1573
3. Yaccoby S., Barlogie B., and Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92 (1998) 2908-2913
4. Tai Y.T., Podar K., Mitsiades N., et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101 (2003) 2762-2769
5. Podar K., Tai Y.T., Davies F.E., et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98 (2001) 428-435
6. Falco P., Bringhen S., Avonto I., et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 7 (2007) 945-957
7. Musto P., and D'Auria F. Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Investig Drugs 16 (2007) 1467-1487
8. Sredni B., Caspi R.R., Klein A., et al. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 330 (1987) 173-176
9. Kalechman Y., Zuloff A., Albeck M., Strassmann G., and Sredni B. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate. Blood 85 (1995) 1555-1561
10. Kalechman Y., Shani A., Sotnik-Barkai I., Albeck M., and Sredni B. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action. Cancer Res 53 (1993) 5962-5969
11. Hayun M., Naor Y., Weil M., et al. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway. Biochem Pharmacol 72 (2006) 1423-1431
12. Itoh K., Tezuka H., Sakoda H., et al. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 17 (1989) 145-153
13. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
14. Levy S., Todd S.C., and Maecker H.T. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16 (1998) 89-109
15. Drucker L., Tohami T., Tartakover-Matalon S., et al. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27 (2006) 197-204
16. Higashimoto I., Chihara J., Kakazu T., Kawabata M., Nakajima S., and Osame M. Regulation of eosinophil cell death by adhesion to fibronectin. Int Arch Allergy Immunol 111 (1996) 66-69
17. Scott G., Cassidy L., and Busacco A. Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. J Invest Dermatol 108 (1997) 147-153
18. Rozzo C., Chiesa V., Caridi G., Pagnan G., and Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer 70 (1997) 688-698
19. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., and Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93 (1999) 1658-1667
20. Tohami T., Drucker L., Shapiro H., Radnay J., and Lishner M. Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J 21 (2007) 691-699
21. Lishner M., Zismanov V., Tohami T., Tartakover-Matalon S., Elis A., and Drucker L. Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation. Cell Signal 20 (2008) 2309-2316
22. Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87 (1994) 503-508
23. Bellamy W.T., Richter L., Frutiger Y., and Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59 (1999) 728-733
24. Vacca A., Ribatti D., Presta M., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 (1999) 3064-3073
25. Asosingh K., Radl J., Van Riet I., Van Camp B., and Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 1 (2000) 351-356
26. Alici E., Konstantinidis K.V., Aints A., Dilber M.S., and Abedi-Valugerdi M. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol 32 (2004) 1064-1072
27. Mori Y., Shimizu N., Dallas M., et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104 (2004) 2149-2154
28. Sredni B., Albeck M., Tichler T., et al. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 13 (1995) 2342-2353
29. Kalechman Y., Albeck M., Oron M., et al. Protective and restorative role of AS101 in combination with chemotherapy. Cancer Res 51 (1991) 1499-1503
30. Kalechman Y., Sotnik-Barkai I., Albeck M., and Sredni B. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101). Cancer Res 53 (1993) 1838-1844
31. Van Valckenborgh E., Croucher P.I., De Raeve H., et al. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol 165 (2004) 869-878
32. Alexandrakis M.G., Sfiridaki A., Miyakis S., et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta 379 (2007) 31-35
33. Kirshner J., Thulien K.J., Martin L.D., et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112 (2008) 2935-2945
34. Mannion B.A., Berditchevski F., Kraeft S.K., Chen L.B., and Hemler M.E. Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). J Immunol 157 (1996) 2039-2047
35. Vanderkerken K., De R.H., Goes E., et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 76 (1997) 451-460